News ID: 314270
Published: 0129 GMT June 27, 2021

Iran launches clinical trial for new COVID-19 vaccine Noora

Iran launches clinical trial for new COVID-19 vaccine Noora
TASNIM

Iran on Sunday launched the clinical trial for another homegrown coronavirus vaccine, a day after it started the domestic production of Russia’s Sputnik V vaccine at an Iranian company.

The recombinant Noora vaccine, produced by Baqiyatallah University of Medical Sciences, was put on display during a ceremony in the presence of Chief Commander of the Islamic Revolution Guards Corps (IRGC) Major General Hossein Salami, Iran’s Health Minister Saeed Namaki as well as other Iranian health officials.

“Our 16-month efforts have finally paid off and Noora vaccine has now been produced. During the last four to five months, vaccine studies were performed on mice, rabbits and monkeys, and the results of the studies were presented to the Health Ministry,” Hassan Abolqassemi, the president of Baqiyatallah University of Medical Sciences, said at the ceremony, Press TV reported.

He noted that that all laboratory tests of the vaccine have been carried out by the Food and Drug Administration of Iran.

“The Noora vaccine, which starts its first clinical phase today, is a recombinant vaccine. It has few side effects and offers high levels of protection. We expect to receive the license for local use from the Ministry of Health immediately after completing phases 1, 2 and 3 of clinical tests,” Abolqassemi said.

“We hope to produce one million doses of the vaccine at the first stage, and quickly increase the production to three million doses per month,” he added.

On Saturday, Iran’s Actoverco pharmaceutical firm produced a test batch of Russia’s Sputnik V vaccine.

The Russian Direct Investment Fund said Iran is the first country in the Middle East to produce the vaccine against COVID-19, adding it will help accelerate vaccinations.

Iran approved Sputnik V for domestic use in January.

Leader of Iran’s Islamic Revolution Ayatollah Seyyed Ali Khamenei on Friday received his first dose of the COVIran Barekat vaccine, which was approved for emergency mass application by the country’s Health Ministry earlier this month.

After receiving the vaccine, the Leader thanked all those involved in the development of the homegrown vaccine.

The Iranian health minister announced earlier this month that the permit for using the Pasteur vaccine — which has been jointly developed by Iran and Cuba — would be issued soon.

“In the near future, the Razi and Fakhra vaccines will also be added to the list of usable [Iranian COVID-19] vaccines,” Namaki said.

The Razi vaccine, officially known as Razi COV-Pars, is an Iranian homegrown vaccine and a product of the Razi Vaccine and Serum Research Institute, which is administered via injection and inhalation.

Fakhra, also an all-Iranian vaccine, is developed by the Defense Ministry’s research center, formerly headed by nuclear scientist Mohsen Fakhrizadeh, who was assassinated in a suspected Israeli-linked terror attack late last year.

In addition to producing domestic vaccines, Iran has imported reliable foreign vaccines from Russia, China, India and Cuba.

 

 

   
KeyWords
 
Comments
Comment
Name:
Email:
Comment:
Security Key:
Captcha refresh
Page Generated in 0/1427 sec